A RANDOMIZED, PLACEBO-CONTROLLED, TRIPLE-BLIND CLINICAL TRIAL TO INVESTIGATE TREATMENT EFFECTS AND SAFETY OF GINKGO BILOBA EXTRACT EGB 761® IN PARTICIPANTS WITH COGNITIVE IMPAIRMENT ASSOCIATED WITH POST-COVID-19 SYNDROME

Conditions

COGNITIVE IMPAIRMENT ASSOCIATED WITH POST-COVID-19 SYNDROME

Brief summary

Change from baseline to Week 6 and Week 12 in the following test scores: • Digit span forward and backward test • Verbal fluency test • TMT (A + B) • CVLT • d2-R, Change from baseline to Week 6 and Week 12 in the following questionnaire scores: • GAD-7 test • PHQ-9 tes, Change from baseline to Week 6 and Week 12 in the 11-point box scale score for vertigo and tinnitus, Change from baseline to Week 6 and Week 12 in the following test/questionnaire scores: • CGI-S • PCFSS • MFIS • mPEM-DSQ • SBQ-LC test • CGI-I at Week 6 and Week 12, Number of patients with AEs, ADRs and SAEs

Related papers

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Interventions

DRUGTebonin konzent 240 mg

DRUGFilm-coated

DRUGround

DRUGyellow tablet for oral use with no active substance

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline to Week 6 and Week 12 in the following test scores: • Digit span forward and backward test • Verbal fluency test • TMT (A + B) • CVLT • d2-R, Change from baseline to Week 6 and Week 12 in the following questionnaire scores: • GAD-7 test • PHQ-9 tes, Change from baseline to Week 6 and Week 12 in the 11-point box scale score for vertigo and tinnitus, Change from baseline to Week 6 and Week 12 in the following test/questionnaire scores: • CGI-S • PCFSS • MFIS • mPEM-DSQ • SBQ-LC test • CGI-I at Week 6 and Week 12, Number of patients with AEs, ADRs and SAEs	—

Measure

Time frame

Change from baseline to Week 6 and Week 12 in the following test scores: • Digit span forward and backward test • Verbal fluency test • TMT (A + B) • CVLT • d2-R, Change from baseline to Week 6 and Week 12 in the following questionnaire scores: • GAD-7 test • PHQ-9 tes, Change from baseline to Week 6 and Week 12 in the 11-point box scale score for vertigo and tinnitus, Change from baseline to Week 6 and Week 12 in the following test/questionnaire scores: • CGI-S • PCFSS • MFIS • mPEM-DSQ • SBQ-LC test • CGI-I at Week 6 and Week 12, Number of patients with AEs, ADRs and SAEs

—

Countries

Germany, Poland, Spain

Outcome results

None listed